Skip to main content
Apontis Pharma AG logo

Apontis Pharma AG — Investor Relations & Filings

Ticker · APPH ISIN · DE000A3CMGM5 LEI · 894500ETO1J6MR8PDF91 F Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2022-05-10 Investor Presentation
Country DE Germany
Listing F APPH

About Apontis Pharma AG

https://apontis-pharma.de/en/

Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.

Recent filings

Filing Released Lang Actions
3M22 Unaudited Results
Investor Presentation Classification · 1% confidence The document text explicitly states "3M 2022 Results" and provides detailed financial highlights for Q1 2022, including Revenue, EBITDA, Gross Profit, and a Balance Sheet as of March 31, 2022. This content structure—a presentation summarizing period-specific financial performance—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it presents the key financial results and operational updates for a specific quarter (Q1 2022) rather than the full annual performance (10-K) or a formal, comprehensive report document, it aligns best with an Earnings Release (ER) or potentially an Investor Presentation (IP) if it were clearly structured as slides for investors. Given the focus on 'Financial Highlights Q1 2022' and the presentation format, ER is the most appropriate classification for the initial results announcement, although it contains more detail than a typical press release, leaning towards an Investor Presentation (IP) or a detailed Earnings Release. However, the presence of detailed financial tables and management commentary on results strongly suggests it is the primary release of those results. Comparing ER (initial announcement, key highlights) vs IR (comprehensive report for a shorter period), this document seems to be the comprehensive summary of the quarterly results, making it closer to an Interim Report (IR) or a detailed Investor Presentation (IP). Since it is a presentation format ('The following presentation...') detailing the results, Investor Presentation (IP) is a strong candidate. Given the explicit financial results summary, I will classify it as an Investor Presentation (IP) as it is a presentation deck detailing the quarterly results, which often overlaps with ER content but is delivered in presentation format.
2022-05-10 English
APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with pan-European intellectual property rights
Regulatory Filings Classification · 1% confidence The document is a press release dated May 5, 2022, announcing a development partnership between APONTIS PHARMA AG and Develco Pharma regarding two new Single Pills. It details strategic business developments, product pipeline expansion, and intellectual property rights. This type of announcement, which is a corporate news item about a strategic agreement rather than a mandatory periodic financial report (like 10-K or IR) or a specific event report (like AGM or DIV), fits best under the general 'Regulatory Filings' category, which often serves as a catch-all for significant, non-standard corporate news disseminated via services like DGAP (indicated in the footer). Since it is not a formal financial report, a management discussion, or a specific transaction report, RNS (Regulatory Filings) is the most appropriate classification.
2022-05-05 English
APONTIS PHARMA: START study published in scientific journal - Cost reduction in the treatment of cardiovascular patients by Single Pill therapy
Legal Proceedings Report Classification · 1% confidence The document is a press release dated April 20, 2022, disseminated via DGAP-News. The content announces the publication of results from the 'START study' in a scientific journal, detailing pharmacoeconomic benefits of Single Pill therapy for cardiovascular patients. This is not a formal regulatory filing like a 10-K or IR, nor is it a management discussion (MDA) or earnings release (ER). It is an announcement about scientific/research findings relevant to investors and the market. Since it is a specific announcement about a scientific publication and its implications, it doesn't fit perfectly into the main financial report categories. However, it is a corporate news item that is not a dividend notice, director dealing, or capital change. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news announcement disseminated through a service like DGAP that doesn't match a more specific category like ER, IR, or CT. It is a general corporate announcement.
2022-04-20 English
Annual financial statements 2021
Annual Report Classification · 1% confidence The document is explicitly titled 'ANNUAL REPORT 2021' and contains comprehensive sections including an interview with the management board, research highlights, operational updates, and strategic outlooks. It is a full-length corporate document detailing the company's performance and activities for the 2021 fiscal year, fitting the definition of a 10-K/Annual Report. FY 2021
2022-03-30 English
Declaration of Compliance 2021 (German only)
Governance Information Classification · 1% confidence The document is titled 'Erklärung zur Unternehmensführung' (Declaration on Corporate Governance) for the fiscal year 2021, citing §§ 289f, 315d HGB. This is a mandatory report in Germany detailing a company's corporate governance structure, board composition, compliance systems, and adherence to the German Corporate Governance Code (DCGK). It is a governance-specific report rather than a full annual report or a simple announcement, fitting the 'Governance Information' category.
2022-03-30 German
Annual financial statements 2021
Annual Report Classification · 1% confidence The document is explicitly titled 'ANNUAL REPORT 2021' for APONTIS PHARMA. It contains comprehensive sections including an interview with the management board, research highlights, sales data, and operational overviews. Given the length and the nature of the content (a full annual report), it is classified as an Annual Report. FY 2021
2022-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.